An Exploratory Phase II Study to Determine the Safety, Tolerability, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults with DSM-5 Intermittent Explosive Disorder (IED)
Clinical Trial Grant
Administered By
School of Medicine
Awarded By
Azevan Pharmaceuticals, Inc.
Start Date
November 3, 2014
End Date
September 22, 2015
Administered By
School of Medicine
Awarded By
Azevan Pharmaceuticals, Inc.
Start Date
November 3, 2014
End Date
September 22, 2015